Addex Therapeutics
SK4
Addex Therapeutics trades on the Swiss SIX exchange [ADXN] and is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including G-Protein Coupled Receptors (GPCRs), receptor tyrosine kinases (RTKs) and cytokine receptors, such as the TNF receptor superfamily. Many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery.
Sector
Biopharmaceuticals
Strategy
Status
Exit
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.